• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atrial fibrillation, an equivalent of cardiovascular disease risk.

作者信息

Barrios Vivencio, Escobar Carlos

机构信息

Cardiology Department, University Hospital Ramon y Cajal, Carretera de Colmenar Viejo, Km 9.100, 28034 Madrid, Spain.

Cardiology Department, University Hospital La Paz, Carretera de Colmenar Viejo, Km 9.100, 28034 Madrid, Spain.

出版信息

Eur Heart J. 2020 Dec 21;41(48):4599. doi: 10.1093/eurheartj/ehaa771.

DOI:10.1093/eurheartj/ehaa771
PMID:33167010
Abstract
摘要

相似文献

1
Atrial fibrillation, an equivalent of cardiovascular disease risk.心房颤动，等同于心血管疾病风险。
Eur Heart J. 2020 Dec 21;41(48):4599. doi: 10.1093/eurheartj/ehaa771.
2
Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure.
Eur Heart J. 2020 Dec 21;41(48):4600. doi: 10.1093/eurheartj/ehaa774.
3
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.比较 CMS 医疗保险人群中老年非瓣膜性心房颤动患者使用直接口服抗凝剂与华法林的临床结局。
J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5.
4
Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.基于保险理赔数据的 18-74 岁非瓣膜性心房颤动日本患者的口服抗凝药物使用情况：一项回顾性分析。
Fam Pract. 2019 Nov 18;36(6):685-692. doi: 10.1093/fampra/cmz016.
5
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.新型口服抗凝剂与华法林预防房颤患者中风和其他心血管事件的成本效益比较。
Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.
6
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.老年 Medicare 患者在非瓣膜性心房颤动中接受达比加群或华法林治疗的心血管、出血和死亡率风险。
Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.
7
Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.达比加群与华法林相比用于心脏复律及不良事件风险的全国性队列研究
PLoS One. 2015 Oct 29;10(10):e0141377. doi: 10.1371/journal.pone.0141377. eCollection 2015.
8
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.老年 Medicare 患者口服抗凝药治疗非瓣膜性心房颤动的卒中、出血和死亡率比较。
Am J Med. 2019 May;132(5):596-604.e11. doi: 10.1016/j.amjmed.2018.12.023. Epub 2019 Jan 9.
9
Blood pressure targets in atrial fibrillation.
Eur Heart J. 2020 Aug 7;41(30):2860-2862. doi: 10.1093/eurheartj/ehaa319.
10
[New oral anticoagulants in nonvalvular atrial fibrillation].[非瓣膜性心房颤动中的新型口服抗凝药]
Presse Med. 2013 Sep;42(9 Pt 1):1225-31. doi: 10.1016/j.lpm.2013.06.004. Epub 2013 Aug 1.

引用本文的文献

1
Association between oral health and atrial fibrillation: A systematic review.口腔健康与心房颤动之间的关联：一项系统综述。
Heliyon. 2022 Mar 23;8(3):e09161. doi: 10.1016/j.heliyon.2022.e09161. eCollection 2022 Mar.